JP7717687B2 - 腎疾患における抗幹細胞因子抗体及びその使用方法 - Google Patents

腎疾患における抗幹細胞因子抗体及びその使用方法

Info

Publication number
JP7717687B2
JP7717687B2 JP2022517173A JP2022517173A JP7717687B2 JP 7717687 B2 JP7717687 B2 JP 7717687B2 JP 2022517173 A JP2022517173 A JP 2022517173A JP 2022517173 A JP2022517173 A JP 2022517173A JP 7717687 B2 JP7717687 B2 JP 7717687B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
amino acid
scf248
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022517173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547733A5 (enExample
JP2022547733A (ja
Inventor
マーティン フィリップス，
Original Assignee
オプシディオ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オプシディオ， エルエルシー filed Critical オプシディオ， エルエルシー
Publication of JP2022547733A publication Critical patent/JP2022547733A/ja
Publication of JP2022547733A5 publication Critical patent/JP2022547733A5/ja
Priority to JP2025123268A priority Critical patent/JP2025165991A/ja
Application granted granted Critical
Publication of JP7717687B2 publication Critical patent/JP7717687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022517173A 2019-09-16 2020-09-16 腎疾患における抗幹細胞因子抗体及びその使用方法 Active JP7717687B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025123268A JP2025165991A (ja) 2019-09-16 2025-07-23 腎疾患における抗幹細胞因子抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900927P 2019-09-16 2019-09-16
US62/900,927 2019-09-16
PCT/US2020/050974 WO2021055409A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof in renal disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025123268A Division JP2025165991A (ja) 2019-09-16 2025-07-23 腎疾患における抗幹細胞因子抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022547733A JP2022547733A (ja) 2022-11-15
JP2022547733A5 JP2022547733A5 (enExample) 2023-09-22
JP7717687B2 true JP7717687B2 (ja) 2025-08-04

Family

ID=74868426

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022517173A Active JP7717687B2 (ja) 2019-09-16 2020-09-16 腎疾患における抗幹細胞因子抗体及びその使用方法
JP2022517136A Active JP7698635B2 (ja) 2019-09-16 2020-09-16 抗幹細胞因子抗体及びその使用方法
JP2025099435A Pending JP2025125563A (ja) 2019-09-16 2025-06-13 抗幹細胞因子抗体及びその使用方法
JP2025123268A Pending JP2025165991A (ja) 2019-09-16 2025-07-23 腎疾患における抗幹細胞因子抗体及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022517136A Active JP7698635B2 (ja) 2019-09-16 2020-09-16 抗幹細胞因子抗体及びその使用方法
JP2025099435A Pending JP2025125563A (ja) 2019-09-16 2025-06-13 抗幹細胞因子抗体及びその使用方法
JP2025123268A Pending JP2025165991A (ja) 2019-09-16 2025-07-23 腎疾患における抗幹細胞因子抗体及びその使用方法

Country Status (28)

Country Link
US (6) US20220324957A1 (enExample)
EP (3) EP4650367A3 (enExample)
JP (4) JP7717687B2 (enExample)
KR (1) KR20220079561A (enExample)
CN (2) CN114729036B (enExample)
AR (1) AR119979A1 (enExample)
AU (2) AU2020351138A1 (enExample)
BR (1) BR112022004776A2 (enExample)
CA (2) CA3154648A1 (enExample)
CL (1) CL2022000633A1 (enExample)
CO (1) CO2022003661A2 (enExample)
DK (1) DK4031569T3 (enExample)
DO (1) DOP2022000058A (enExample)
EC (1) ECSP22022676A (enExample)
ES (1) ES3053942T3 (enExample)
FI (1) FI4031569T3 (enExample)
IL (1) IL291385A (enExample)
MX (1) MX2022003159A (enExample)
PE (1) PE20230090A1 (enExample)
PH (1) PH12022550647A1 (enExample)
PL (1) PL4031569T3 (enExample)
PT (1) PT4031569T (enExample)
SA (1) SA522431966B1 (enExample)
TW (1) TWI875812B (enExample)
UA (1) UA129546C2 (enExample)
UY (1) UY38883A (enExample)
WO (2) WO2021055408A1 (enExample)
ZA (1) ZA202203272B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US20220324957A1 (en) 2019-09-16 2022-10-13 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease
KR20250167153A (ko) * 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
WO2026079764A1 (ko) * 2024-10-10 2026-04-16 아주대학교산학협력단 마우스 scf를 중화하는 항체 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505057A (ja) 2011-01-10 2014-02-27 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 幹細胞因子阻害剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
HUT62011A (en) * 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
JP3583214B2 (ja) 1995-12-01 2004-11-04 株式会社ニチレイ ヒトｓｃｆに対するモノクローナル抗体
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
RU2407752C2 (ru) 2004-04-29 2010-12-27 Оцука Фармасьютикал Ко., Лтд. Антитела к гликопротеину vi и способы продуцирования и использования этих антител
WO2006002064A2 (en) 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
US20080248050A1 (en) 2006-06-30 2008-10-09 Uchicago Argonne, Llc Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine
WO2009127046A1 (en) 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
KR101384360B1 (ko) 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
US10927153B1 (en) 2015-05-20 2021-02-23 University Of South Florida Synthetic plasmodium antigens, compositions, and uses thereof
EP3337827B1 (en) 2015-08-19 2026-07-08 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
KR20170022409A (ko) 2015-08-20 2017-03-02 주식회사 와이바이오로직스 Scf 특이적 항체
US11091559B2 (en) * 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
MX2018007818A (es) 2015-12-22 2019-07-01 Abbvie Stemcentrx Llc Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
TWI773693B (zh) 2016-10-05 2022-08-11 新加坡商細胞研究私人有限公司 從臍帶的羊膜分離間質幹細胞的方法、從臍帶的羊膜分離的間質幹細胞群以及用於從臍帶的羊膜分離間質幹細胞的細胞培養基
WO2019066093A1 (ko) 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
WO2019088658A1 (ko) 2017-10-31 2019-05-09 주식회사 컴워스파마 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
KR102131898B1 (ko) 2017-10-31 2020-07-08 주식회사 노벨티노빌리티 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
CN120305401A (zh) 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
US20220324957A1 (en) 2019-09-16 2022-10-13 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease
JP2024511027A (ja) 2021-03-17 2024-03-12 オプシディオ， エルエルシー 幹細胞因子抗体及びその使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505057A (ja) 2011-01-10 2014-02-27 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 幹細胞因子阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fonseca, W. et al.，Group 2 innate lymphoid cells (ILC2) are regulated by stem cell factor during chronic asthmatic disease，Mucosal Immunology，2019年01月07日，Vol.12, No.2，p.445-456，doi:10.1038/s41385-018-0117-1

Also Published As

Publication number Publication date
US20240076367A1 (en) 2024-03-07
UY38883A (es) 2021-04-30
TW202124434A (zh) 2021-07-01
EP4031569A4 (en) 2023-10-18
JP2022548646A (ja) 2022-11-21
CA3154649A1 (en) 2021-03-25
EP4031176A4 (en) 2023-11-29
DOP2022000058A (es) 2022-08-31
UA129546C2 (uk) 2025-05-28
US20220340655A1 (en) 2022-10-27
DK4031569T3 (da) 2025-11-17
US20230019680A1 (en) 2023-01-19
CN118561997A (zh) 2024-08-30
PL4031569T3 (pl) 2026-02-16
FI4031569T3 (fi) 2025-11-14
MX2022003159A (es) 2022-04-07
US11939373B2 (en) 2024-03-26
ES3053942T3 (en) 2026-01-28
PH12022550647A1 (en) 2023-03-27
US20210079084A1 (en) 2021-03-18
TWI875812B (zh) 2025-03-11
EP4650367A2 (en) 2025-11-19
BR112022004776A2 (pt) 2022-06-21
SA522431966B1 (ar) 2025-05-18
WO2021055409A1 (en) 2021-03-25
JP2022547733A (ja) 2022-11-15
EP4031176A1 (en) 2022-07-27
PE20230090A1 (es) 2023-01-16
AU2020351138A1 (en) 2022-03-31
CL2022000633A1 (es) 2022-11-11
AU2020348295A1 (en) 2022-04-07
CO2022003661A2 (es) 2022-04-08
EP4031569A1 (en) 2022-07-27
AR119979A1 (es) 2022-01-26
WO2021055408A1 (en) 2021-03-25
ZA202203272B (en) 2022-12-21
EP4031569B1 (en) 2025-08-20
CN114729036A (zh) 2022-07-08
CA3154648A1 (en) 2021-03-25
US20260193336A1 (en) 2026-07-09
US12410246B2 (en) 2025-09-09
KR20220079561A (ko) 2022-06-13
JP7698635B2 (ja) 2025-06-25
TW202523696A (zh) 2025-06-16
ECSP22022676A (es) 2022-05-31
IL291385A (en) 2022-05-01
CN114729036B (zh) 2024-07-02
JP2025125563A (ja) 2025-08-27
PT4031569T (pt) 2025-11-12
JP2025165991A (ja) 2025-11-05
EP4650367A3 (en) 2026-03-04
US20220324957A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US12168688B2 (en) Antibodies and variants thereof against PD-L1
JP2025165991A (ja) 腎疾患における抗幹細胞因子抗体及びその使用方法
CN116783215A (zh) 抗cd93构建体及其用途
CA3212098A1 (en) Stem cell factor antibodies and methods of use thereof
CA3231124A1 (en) Antibodies targeting ccr2
RU2844744C1 (ru) Антитела против фактора стволовых клеток и способы их применения
HK40112825A (en) Anti-stem cell factor antibodies and methods of use thereof
US8716235B2 (en) Method for inhibiting metastasis by using anti-CCL3 antibodies
HK40078116A (en) Anti-stem cell factor antibodies and methods of use thereof
HK40078116B (en) Anti-stem cell factor antibodies and methods of use thereof
WO2025049343A1 (en) Anti-tslp antibody constructs and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250723

R150 Certificate of patent or registration of utility model

Ref document number: 7717687

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150